Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Phase 2
- Conditions
- Autism Spectrum Disorder
- Registration Number
- NCT05494398
- Lead Sponsor
- Stanford University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Inclusion Criteria:<br><br> - participation in an associated single-dose (IRB-54931, NCT04278898) or randomized,<br> controlled trial of NAC (IRB-63262, NCT05664789).<br><br> - stable medication regimens (= 30 days) with no anticipated changes during the trial.<br><br>Exclusion criteria:<br><br>• the presence of significant medical problems that reduce medical stability.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI);Change in restricted and repetitive behaviors as measured by Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder (CYBOCS-ASD)
- Secondary Outcome Measures
Name Time Method Change in Gamma band amplitude and synchronization measured by electroencephalography (EEG);Change in restricted repetitive behavior subtypes as measured by the Restricted Behavior Scale - Revised (RBS-R)